Invitrx Therapeutics

FOR IMMEDIATE PRESS RELEASE

FDA Lifts Warning Letter Related to Reluma Skincare Against Invitrx Therapeutics

Irvine, CA., May 6, 2020 — Invitrx Therapeutics, a biotechnology company pioneering in regenerative cell therapy announced today that it received letters from the United Stated Food and Drug Administration (FDA) closing out warning letters received by the company in February 2017 related to Reluma Skincare. Regarding to Invitrx Therapeutics's latest actions, the FDA had lifted a warning letter from March 31, 2020 against Invitrx Therapeutics.

The removal of the warning letters is a reflection of the exceptional quality and operations team at Invitrx Therapeutics. Over the past three years, Invitrx Therapeutics' team have worked diligently with the FDA to fully address the issues and help to instill a culture within the company that is committed to quality and compliance. The lifting of Reluma Skincare issues is a significant boost and improves the company's ability to drive the growth of the business. Invitrx Therapeutics is committed to continuing and strengthening this company wide emphasis on excellence.

To learn more about Invitrx Therapeutics and all of the latest news and innovative products please visit www.invitrx.com or email info@invitrx.com.

About Invitrx Therapeutics: Headquartered in Irvine, California, is a global research- based life science company with more than 15 years of experience in the harvesting and isolation of stem cells in order to discover, develop, manufacture, and commercialize innovative products. Invitrx Therapeutics prime focus is in advancing the field of regenerative medicine through scientific research and development. Invitrx Therapeutics is built upon a team with expertise in each zone of regenerative medicine including scientific, clinical, and regulatory affairs.